Eleni Paschalidou

Ms. Eleni Paschalidou


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2024 in Clinics and Practice
Verified
Journal Article
Open access
PDF file
Eleni PaschalidouEleni Paschalidou
Eleni Paschalidou
Georgios N. KatsarasGeorgios N. Katsaras
Georgios N. Katsaras
TPThomas Papoulakis
Thomas Papoulakis
EKEvangelia Kalloniati
Evangelia Kalloniati
Dimitrios KavvadasDimitrios Kavvadas
Dimitrios Kavvadas
Theodora PapamitsouTheodora Papamitsou
Theodora Papamitsou
Background: Isotretinoin is the drug of choice for severe acne. We sought to examine the potential link between isotretinoin and insulin resistance. Methods: We conducted a systematic review and meta-analysis in accordance with the PRISMA statement. A comprehensive search of the PubMed/MEDLINE, SCOPUS, and Cochrane databases was performed until 12 January 2022 utilizing the PICO (Patient, Intervention, Comparison, Outcome) tool. Fifteen English-language studies focusing on isotretinoin-treated acne patients were included. Serum levels of insulin, glucose, and adiponectin were evaluated before and after treatment, and insulin sensitivity was assessed using the HOMA–IR. A meta-analysis was conducted using RevMan 5.4.1 software, and a quality assessment was undertaken using the ROBINS-I tool. Results: The meta-analysis unveiled a statistically significant rise in the post-treatment levels of adiponectin, an anti-inflammatory agent, which inhibits liver glucose production while enhancing insulin sensitivity (SMD = 0.86; 95% confidence interval (95% CI) = 0.48–1.25, p-value < 0.0001; I2 = 58%). Our subgroup analysis based on study type yielded consistent findings. However, no statistically significant outcomes were observed for insulin, glucose levels, and the HOMA-IR. Conclusions: There is not a clear association between isotretinoin and insulin resistance, but it appears to enhance the serum levels of adiponectin, which participates in glucose metabolism.

13 December 2023 in Current Pharmacology Reports
Verified
Journal Article
Closed access
PDF file
Eleni PaschalidouEleni Paschalidou
Eleni Paschalidou
PTPhilippos Tasioudis
Philippos Tasioudis
Georgios N. KatsarasGeorgios N. Katsaras
Georgios N. Katsaras
TPThomas Papoulakis
Thomas Papoulakis
DKDorothea Kapoukranidou
Dorothea Kapoukranidou
Theodora PapamitsouTheodora Papamitsou
Theodora Papamitsou

15 September 2022
Verified
Preprint
Open access
Eleni PaschalidouEleni Paschalidou
Eleni Paschalidou
PTPhilippos Tasioudis
Philippos Tasioudis
GKGeorgios Katsaras
Georgios Katsaras
TPThomas Papoulakis
Thomas Papoulakis
DKDorothea Kapoukranidou
Dorothea Kapoukranidou
TPTheodora Papamitsou
Theodora Papamitsou
Background: Facial angiofibromas (FAs) are common skin manifestations of tuberous sclerosis complex (TSC) that occur in up to 80% of patients. Rapamycin seems to be effective in decreasing FAs. Objective: The aim of our study was to investigate the efficacy and safety of topically applied rapamycin in TSC patients with FAs. Methods: The methods and the results were carried out according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement. PubMed/MEDLINE, SCOPUS, and Cochrane database were systematically searched until April 21, 2022, using the PICO tool (Patient, Interventions, Comparisons, Outcome). Studies regarding efficacy and/or safety of topical sirolimus for the treatment of FAs in TSC with a published full-text in English were included. Safety was assessed based on adverse effects and sirolimus’ blood levels, and efficacy was documented by clinical improvement and reduction of Facial Angiofibroma Severity Index (FASI). For Meta-analysis, Review Manager (RevMan) 5.4.1 software was used, using random-effects model and standardized mean difference (SMD) with 95% confidence interval (CI). Results: Twenty-one final studies were included. Regarding safety, in the included studies the observed adverse effects were mainly local, while the blood levels of rapamycin were within safe limits, decreasing the likelihood of systemic immunosuppression. The meta-analysis revealed a statistically significant decrease in post-treatment FASI (SMD: -1.31, 95% CI: [-1.85,-0.77], p-value <0.00001). Subgroup and sensitivity analyses indicated similar findings. No publication bias was found to this association. Conclusion: The application of topical sirolimus to FAs can safely decrease their severity in patients with TSC.

31 March 2022
Verified
Preprint
Open access
Eleni PaschalidouEleni Paschalidou
Eleni Paschalidou
Georgios N. KatsarasGeorgios N. Katsaras
Georgios N. Katsaras
TPThomas Papoulakis
Thomas Papoulakis
EKEvangelia Kalloniati
Evangelia Kalloniati
DKDimitrios Kavvadas
Dimitrios Kavvadas
TPTheodora Papamitsou
Theodora Papamitsou
Aim: Isotretinoin, the drug of choice for severe - nodulocystic acne, might be associated with an increase in insulin resistance. We aimed to investigate this association. Methods: We performed a systematic review and meta-analysis according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Statement. A systematic search in PubMed/MEDLINE, SCOPUS and Cochrane databases was conducted until the 12th of January 2022 using the PICO tool (Patient, Intervention, Comparison, Outcome). Studies with a published full text in English regarding acne patients under isotretinoin were included. Insulin, glucose and adiponectin serum levels before and after isotretinoin treatment were recorded and insulin sensitivity was assessed using the homeostasis model assessment of insulin resistance (HOMA–IR). For Meta-analysis, the Review Manager (RevMan) 5.4.1 software was utilized. The quality assessment of the included studies was performed using the ROBINS-I tool. Results: Fifteen studies were included. The meta-analysis revealed a statistically significant increase in post-treatment adiponectin [SMD = 0.86; 95% confidence interval (CI) = 0.48 - 1.25, p-value <0.0001; I2 = 58%]. Subgroup analysis by study type revealed the same results [cohort studies pooled SMD = 1.2, 95% CI = 0.81 -1.61, p-value <0.00001; I2 = 8% and case-control studies pooled SMD = 0.53, 95% CI = 0.16 - 0.9, p-value=0.005; I2 = 27%)]. No statistically significant results were shown for insulin, glucose levels and HOMA-IR. Conclusion: Although isotretinoin exposure is not clearly associated with insulin resistance, it seems that it can increase serum adiponectin levels. Further research is needed to clarify this association.